Li-Ming Gan

Li-Ming Gan is a seasoned professional in the biotechnology and pharmaceutical industries, currently serving as CEO and Co-Founder of Ribocure Pharmaceuticals AB since January 2022, a company dedicated to the research and development of oligonucleotide therapeutics. In addition, Li-Ming Gan holds the position of Co-CEO, President of Global R&D, and Chief Medical Officer at Suzhou Ribo Life Science Co., Ltd, the parent company specializing in oligonucleotide research. With an academic background as a Professor and Chief Physician in translational cardiovascular research at Sahlgrenska University Hospital and the University of Gothenburg, Li-Ming Gan has been involved in the institution since 2006. Previous roles at AstraZeneca from 2006 to January 2022 include Vice President, Head of Early Clinical Development, and Senior Medical Science Director, focusing on phase I and II clinical trials and cardiovascular research initiatives.